Recombinant Human IFN-gamma Biotinylated Protein, CF

When Recombinant Human IFN-gamma R1/CD119 (673-IR/CF) is immobilized at 3 µg/mL (100 µL/well), Biotinylated Recombinant Human IFN-gamma Protein (Catalog # BT285) binds with an ED50 of 3.00-27.0 ng/mL.

2 μg/lane of Recombinant Human IFN-gamma Biotinylated Protein (Catalog # BT285) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 14-20 kDa.

• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IFN-gamma Biotinylated Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human IFN-gamma R1/CD119 (Catalog # 673-IR/CF) is immobilized at 3 µg/mL (100 µL/well), Biotinylated Recombinant Human IFN-gamma (Catalog # BT285) binds with an ED₅₀ of 3.00-27.0 ng/mL.
• Source: E. coli-derived human IFN-gamma protein
  Gln24-Gln166, with a N-terminal Met
• Accession #: CAA31639.1
• N-terminal Sequence: Met
• Structure / Form: Biotinylated via Amines
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 16.9 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 14-20 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Sodium Succinate, Mannitol and Tween®® 80.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile, deionized water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IFN-gamma Biotinylated Protein, CF

• IFG
• IFI
• IFNG
• IFNgamma
• IFN-gamma
• Immune interferon
• interferon gamma
• interferon, gamma

Background

Interferon-gamma (IFN-gamma ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). It shares 90% amino acid (aa) sequence identity with rhesus IFN-gamma, 59%‑64% with bovine, canine, equine, feline, and porcine IFN‑ gamma, and 37%‑43% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI ( alpha subunits) which then interact with IFN-gamma RII ( beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up‑regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (7).

1. Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
3. Gray, P.W. and D.V. Goeddel (1982) Nature 298:859.
4. Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. 92:5401.
5. Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
6. Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
7. McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. 20:125.
8. Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. 3:1247.
9. Kelchtermans, H. et al. (2008) Trends Immunol. 29:479.

FAQs for IFN-gamma (BT285). (Showing 1 - 1 of 1 FAQ).

1. Is Recombinant Human IFN-gamma Protein - Clinical grade or preclinical ?
   • We are research use only.

Bioinformatics

• Uniprot:
  • CAA31639.1()